Pradaxa - the Anticoagulant Gets Nod of Approval from US

by Rathi Manohar on  October 21, 2010 at 7:59 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The anticoagulant, Pradaxa which is administered to reduce the risk of stroke in people who suffer atrial fibrillation has been approved by the Food and Drug Administration in the US.
 Pradaxa - the Anticoagulant Gets Nod of Approval from US
Pradaxa - the Anticoagulant Gets Nod of Approval from US

More than two million Americans have atrial fibrillation, one of the most common ailments involving irregular heartbeat.

"People with atrial fibrillation are at a higher risk of developing blood clots, which can cause a disabling stroke if the clots travel to the brain," Dr Norman Stockbridge, director of the FDA's division of cardiovascular and renal products, said in a statement.

Pradaxa, marketed by Germany's Boehringer Ingelhei, is an anticoagulant that works to neutralize thrombin, an enzyme essential in blood coagulation.

The drug's safety and efficacy was tested in clinical studies comparing it with warfarin.

Praxada does not require patients to have regular blood testing.

But like other anti-clotting drugs, it can have adverse effects, including life-threatening bleeding, gastrointestinal symptoms, stomach pain, nausea, heartburn and bloating.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive